A First-in-Human Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of MAX-40070 in Healthy Subjects
Latest Information Update: 06 Dec 2023
At a glance
- Drugs MAX-40070 (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; First in man
- Sponsors Maxinovel Pharmaceuticals
- 25 Jan 2022 New trial record